
	Where results make sense

Topic: Biogen

Related Topics

Biogen Idec

biogenic substance

Biogenic amine

Biogen Idec Inc

In the News (Fri 27 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Biogen IDEC - Home
		Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI® for Crohn's Disease
		Biogen Idec to present at the Sanford and Bernstein Conference
		Biogen Idec to present at the Sanford and Bernstein Conference - Breakout Session
	www.biogen.com (82 words)

	ITworld.com - Biogen, Idec agree to merge in stock deal
		Biogen, with 2,700 employees worldwide, is based in Cambridge, Massachusetts, and Idec, with 1,000 employees globally, is in San Diego.
		Biogen has biological bulk manufacturing facilities in Cambridge and Research Triangle Park, North Carolina, and a large-scale manufacturing plant in Research Triangle Park to make bulk protein, which the company said is one of the largest cell culture facilities globally.
		Biogen is the world's oldest independent biotech, emerging out of a 1978 meeting of scientists including Phillip Sharp of the Massachusetts Institute of Technology and Walter Gilbert from Harvard University, both of whom are Nobel Prize winners.
	www.itworld.com /Tech/2428/030623biogen/pfindex.html (608 words)

	Ambit Press - Client Success Biogen Idec
		Biogen Idec training tools are now listed on a securely hosted Ambit Web portal that allows the Training Logistics team, as well as those requesting materials, to see exactly what is being ordered.
		Biogen Idec realized that many of these tools would be more user-friendly in CD format, rather than the hard copies previously used.
		But what impressed Biogen Idec the most was Ambit's ability to thoroughly grasp the business task at hand, to think creatively, and to find smart, simple ways to make improvements-improvements that other printers either don't have the expertise to recommend, or the technology to back up.
	www.ambitpress.com /success-biogenidec.htm (656 words)

	Pharmaceutical Technology - Biogen Idec Pharmaceutical Production Facility, Hillerod
		Biogen Idec, the world's third largest biotech company believed that it needed to have new Danish head offices near to its new large-scale manufacturing facility.
		Biogen Idec purchased Conforma Therapeutics Corporation in May 2006 for $150m to obtain their early-stage cancer-fighting technology advances.
		Biogen Idec officials have conceded that the new plant's production costs will be about the same as using third-party manufacturers.
	www.pharmaceutical-technology.com /projects/biogen (1216 words)

	Biogen Idec - Wikipedia, the free encyclopedia
		Biogen Idec is a member of the SandP 500, SandP 1500, and NASDAQ-100.
		Biogen Idec is headquartered in Kendall Square in Cambridge, Massachusetts, and operates research and development facilities in Cambridge and San Diego.
		Biogen Idec maintains its international headquarters in Zug, Switzerland, and operates an International regulatory and clinical center of excellence in Maidenhead, UK.
	en.wikipedia.org /wiki/Biogen (628 words)

	Sample Contracts - Agreement and Plan of Merger - IDEC Pharmaceuticals Corp. and Biogen Inc. - Competitive Intelligence ... (Site not responding. Last check: 2007-10-20)
		Biogen is not in violation of the Biogen Organizational Documents and no Biogen Significant Subsidiary is in violation of its Biogen Subsidiary Organizational Documents, except, in the case of such Biogen Significant Subsidiary, as would not reasonably be likely to have a Material Adverse Effect on Biogen.
		Neither Biogen nor any of its Subsidiaries has received notice of any claim made by a governmental authority in a jurisdiction where Biogen or any of its Subsidiaries, as applicable, does not file a Tax Return, that Biogen or such Subsidiary is or may be subject to taxation by that jurisdiction.
		Biogen has received the opinion of its financial advisor, Goldman, Sachs and Co., dated the date of this Agreement, to the effect that, as of such date, the Exchange Ratio is fair, from a financial point of view, to the holders of Biogen Common Stock.
	contracts.onecle.com /biogen/idec.mer.2003.06.20.shtml (4123 words)

	Suit targets Biogen Idec sales actions \| The San Diego Union-Tribune
		Biogen Idec spokesman Jose Juves said the allegations in Blanton's lawsuit are "without merit." The company filed a countersuit Feb. 4 after becoming aware that Blanton intended to file her complaint.
		Blanton is suing Biogen Idec over her firing, alleging that she is a victim of gender discrimination and retaliation for complaints about the allegedly dubious marketing practice.
		None of the allegations involve Biogen Idec's multiple sclerosis drug Tysabri, which was pulled off the market Feb. 28 after it was linked to the death of one patient and the serious illness of a second patient.
	www.signonsandiego.com /uniontrib/20050309/news_1b9biogen.html (685 words)

	WebWire® \| Biogen Idec Reports First Quarter 2006 Results
		On a reported basis, calculated in accordance with GAAP, Biogen Idec reported net income of $123 million (or EPS of $0.36) in the first quarter of 2006 (Q1 2005: net income of $43 million, or EPS of $0.12).
		Biogen Idec continues to expect that its 2006 non-GAAP earnings per share will be in the range of $1.95 - $2.10.
		Biogen Idec and Elan will continue to work closely with the FDA in the weeks ahead with the goal of making TYSABRI available.
	www.webwire.com /ViewPressRel.asp?aId=13175 (1489 words)

	Disclaimer - Biogen Idec
		Biogen Idec is not engaged in rendering medical or similar professional services or advice via this website, and the information provided is not intended to replace medical advice offered by a physician.
		You should not construe Biogen Idec’s publication of this content as an endorsement by Biogen Idec of the views expressed herein, or any warranty or guarantee of any strategy, recommendation, treatment, action, or application of medication or preparation made by the author of the content.
		Biogen Idec makes no representation that the information in the website is appropriate or available for use in other locations, and access to the Biogen Idec website from territories where the content of the Biogen Idec website may be illegal is prohibited.
	www.biogen.nl /disclaimer (1190 words)

	RTE Business - Biogen issues statement on Avonex
		Pharmaceutical company Biogen, which is Elan's partner in the manufacture of the suspended multiple sclerosis drug Tysabri, has issued a statement on its MS drug Avonex.
		Biogen said today that the US Food and Drug Administration had analysed its figures and found no cases of PML in patients receiving Avonex on its own.
		The company said it and Elan were continuing their extensive evaluation of patients in clinical trials and were staying in close contact with the FDA and other international regulatory authorities.
	www.rte.ie /business/2005/0323/biogen.html (143 words)

	content management customer success stories -Biogen
		In November 2003, Biogen Idec Inc.(NASDAQ: BIIB) was formed from the merger of two of the world’s leading biotechnology companies, Biogen, Inc. and IDEC Pharmaceuticals Corporation.
		Biogen Idec intends to continue its growth through discovery, development and commercialization of its own innovative products and through strategic alliances as the partner-of-choice for biologics development, manufacturing and marketing.
		Biogen Idec is dedicated to pursuing the creativity of science.
	www1.paperthin.com /customers/Biogen.cfm (124 words)

	Idec and Biogen: a natural union?
		Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made last week.
		Biogen and Idec see the arrangement as complimenting one another with benefits to be found in both the short and long term.
		This is despite the disparity in size of the companies; Biogen had revenue of $1.1 billion in 2002, while Idec had 2002 revenue of $404 million.
	www.bioportfolio.com /news/datamonitor_42.htm (913 words)

	FDA raps Biogen's plan to track MS drug's safety - The Boston Globe
		Tim Hunt, a Biogen Idec spokesman, said the company has been working with the FDA since February 2005, when Biogen Idec and Elan voluntarily withdrew Tysbari from the market after two patients taking it in a trial contracted a rare brain disease.
		Biogen Idec shares gained one cent to close at $45.51 on a day when broad market indexes declined sharply.
		In that plan, Biogen Idec had proposed that doctors and patients sign up voluntarily for a registry to track their experience with the drug.
	www.boston.com /business/globe/articles/2006/03/07/fda_raps_biogens_plan_to_track_ms_drugs_safety (820 words)

	Welcome to the Biogen Pro Series Website (Site not responding. Last check: 2007-10-20)
		We at Biogen have tried to interpret the future and the needs of individuals who realise the possibilities of technology in thier diets.
		Biogen brings together all the factors contributing to a healthier more productive and sustainable lifestyle.
		Biogen has scientifically formulated a superior range of nutritional products designed around the needs of individuals seeking an elite method and functionallity to promote and prolong a healthier state of being and mind.
	www.biogen.co.za /index.htm (108 words)

	RTE Business - Biogen Idec affirms 2006's outlook
		Pharmaceutical company Biogen Idec affirmed its outlook for 2006 earnings as it awaits word from the US Food and Drug Administration on whether its withdrawn multiple sclerosis drug Tysabri can be returned to the market.
		Elan and Biogen pulled Tysabri nearly a year ago after it was associated with a potentially fatal brain disorder.
		Mullen said Biogen is working with the FDA on how to educate neurologists about the drug's risks.
	www.rte.ie /business/2006/0111/biogen.html (230 words)

	Biogen IDEC - Investor Relations
		Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader with leading products and capabilities in oncology, neurology and immunology, is committed to transforming scientific discovery into advances in healthcare.
		In addition to Biogen Idec's promising portfolio of drug candidates, the company's capabilities and capacity for protein manufacturing are world-class in quality and scale.
		Biogen Idec is headquartered in Cambridge, MA and was formed in 2003 from the merger of two of the world's leading biotechnology companies, Biogen, Inc., founded in Switzerland in 1978, and IDEC Pharmaceuticals Corporation, founded in San Francisco, CA in 1985.
	investor.biogenidec.com /phoenix.zhtml?c=148682&p=IROL-index (482 words)

	Biogen Research
		Biogen’s research is closely integrated with its commercial strengths, providing for a concentration on developing products in three therapeutic areas Neurology, Dermatology and Rheumatology.
		Biogen’s attention to RandD has helped fuel a promising pipeline of potential therapies that could improve the quality of people’s lives.
		The BAFF pathway is critical for the maturation and survival of B cells, and has therapeutic implications for B-cell mediated autoimmune diseases, such as Lupus and rheumatoid arthritis.
	biogen.biogenidec.com /site/content/research/biogen_research.asp (217 words)

	Biogen News
		Biogen Idec and Syntonix Pharmaceuticals has announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen Idec.
		Biogen Idec Inc. and Elan Corp. said yesterday that they have applied to the Food and Drug Administration for approval to sell Tysabri, a multiple sclerosis drug, to treat patients with Crohn's disease.
		Biogen Idec and Elan Corporation, plc today announced that they received approval from the European Commission to market TYSABRI as a treatment for relapsing remitting multiple sclerosis to delay the...
	www.topix.net /com/bgen (722 words)

	Biogen News - Page 2
		Drugmaker Biogen Idec is set to pad its existing arsenal of treatments for multiple sclerosis through the acquisition of a privately held Swiss firm, Fumapharm AG.
		Biogen Idec and Fumapharm AG announced positive results from a Phase II study designed to evaluate the efficacy and safety of BG-12, an oral fumarate, in patients with relapsing-remitting multiple sclerosis.
		Biogen Idec announced today that data published in the March 14, 2006 issue of Neurology demonstrated that AVONEX delayed the risk of developing clinically definite multiple sclerosis for up to five years in...
	www.topix.net /com/bgen/page2 (1090 words)

	San Diego Source > Search Results > Biogen Idec (Site not responding. Last check: 2007-10-20)
		Rituxan, which is made by Biogen and comarketed by Genentech Inc., is approved to treat non-Hodgkins lymphoma and rheumatoid arthritis.
		Shares of Cambridge, Mass.-based Biogen rose 26 cents to $51.32 on the Nasdaq while American depository shares of Ireland-based Elan rose 24 cents to $14.35 on the New York Stock Exchange.
		Under an amended agreement, Biogen Idec agreed to take 1 million common shares of Targeted Genetics for $5.7 million of debt against the $8.2 million owed.
	www.sddt.com /Search/SearchResults.cfm?Expression=Biogen+Idec (896 words)

	USATODAY.com - It all starts with quality, Biogen Idec CEO says (Site not responding. Last check: 2007-10-20)
		Think also Biogen Idec, a company formed a year ago with the merger of one of the world's original biotech companies and a pharmaceutical leader in cancer and autoimmune diseases.
		Joined Biogen in 1989 after nine years at what is now GlaxoSmithKline.
		Named Biogen Idec CEO in 2000 and chairman in 2002.
	usatoday.com /tech/techinvestor/industry/2004-12-19-biogen-advice_x.htm (1939 words)

	Fool.com: Biogen and the Biotech Investing Checklist (Stock Research) June 20, 2000
		Biogen used the partnership route to good advantage when it was first trying to establish itself.
		Today, Biogen is considered something of a blue chip in its own right and no longer needs to rely upon its larger brethren.
		Biogen should be able to generate positive cash flow going forward, and the company's strong cash position can be used to fund research or make acquisitions or licensing deals with smaller companies to bolster its pipeline.
	www.fool.com /research/2000/foolsden000620.htm (1438 words)

	PRESS RELEASE UCB and Biogen Idec to Collaborate on Oral Multiple Sclerosis Therapy (Site not responding. Last check: 2007-10-20)
		Furthermore Biogen Idec will contribute significantly to clinical costs for Phase II and Phase III studies.
		Biogen Idec creates new standards of care in oncology, neurology and immunology.
		Biogen Idec assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
	www.marketwire.com /mw/release_html_b1?release_id=168575 (758 words)

	Biogen Slows Down [Fool.com] July 26, 2006
		Not all is bad for Biogen, though, as the company does have potential future growth drivers on the way.
		The big news for Biogen and partner Elan (Nasdaq: ELN) this quarter was the return to the U.S. market of its multiple sclerosis drug, Tysabri.
		Besides expanded indications for Rituxan and the Tysabri launch, the rest of Biogen's drug pipeline is in early clinical stages, and it will be a long time before the company could see any revenues from these drugs.
	fool.com /investing/general/2006/07/26/biogen-slows-down.aspx?... (433 words)

	WebWire® \| Biogen Idec And mondoBIOTECH Sign Collaboration And Licensing Agreement To Develop And Commercialize ...
		"Biogen Idec is a premier biotechnology partner with a global structure, excellent clinical development and commercialization capabilities, and a strong record of accomplishments.
		In accordance with the agreement, Biogen Idec will be responsible for the global manufacturing, clinical development, regulatory approval and commercialization of Aviptadil.
		Biogen Idec intends to finalize the development plan for Aviptadil and initiate additional clinical work in 2007.
	www.webwire.com /ViewPressRel.asp?aId=20293 (757 words)

	BIIB - Biogen Idec Inc Stock quote - CNNMoney
		Biogen Idec to acquire privately held Syntonix (Reuters)
		Biogen Idec Initiates Phase III Clinical Program of Oral Compound BG-12 for Multiple...
		Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for...
	money.cnn.com /quote/quote.html?symb=BIIB (295 words)

	Biogen Idec Stock Price (BIIB), Stock Quotes, Charts, Trades, Market News
		Biogen to acquire Syntonix for $40M : CAMBRIDGE, Mass.
		Biogen Idec to invest a further 225 mln usd on Hilleroed plant in Denmark
		Biogen Idec says positive data from Phase I/II study of lumiliximab
	www.advfn.com /quote_biogen-idec---m_nasdaq_biib.html (449 words)

	Imaging Research Inc.: Expression Analysis Collaboration with Biogen Inc.
		Imaging Research is supplying Biogen with multiple copies of ArrayStat software together with statistical consulting services.
		"This collaboration with Biogen is exciting and demonstrates our continuing ability to develop leading-edge solutions for life science research and drug discovery".
		"This will enable Biogen to analyze our gene expression microarrays more rapidly and with increased confidence in our development and use of a variety of array formats," commented a Biogen spokesperson.
	www.imagingresearch.com /company_information/prs/AST_Biogen_coll.asp (276 words)

Try your search on: Qwika (all wikis)